A Prospective, Multicenter Study to Evaluate the JensClip Transcatheter Valve Repair System

Inclusion Criteria: * Age ≥ 18 years; * Echocardiographically confirmed moderate-severe or severe degenerative mitral regurgitation (regurgitation degree MR ≥ 3+); * NYHA Classification II-IV. * LVEF ≥ 20% * Patients considered at high surgical risk after evaluation by two or more cardiovascular specialists (American Association for Thoracic Surgery STS score: risk of death from mitral valve repair ≥ 6% or from mitral valve replacement ≥ 8% (high risk); or the presence of 2 or more indices of frailty (moderate to severe frailty); or the presence of 2 or more major organ insufficiencies that do not improve postoperatively; or a comprehensive cardiac team assessment that the patient has other combined diseases or factors that make him or her unsuitable for surgery) * Anatomically suitable for mitral valve repair and assessed as suitable for use of this investigational device. * Voluntarily participate and sign an informed consent form and be willing to accept relevant examinations and clinical follow-up. Exclusion Criteria: * Severe mitral valve calcification * Previous implantation of a prosthetic mitral valvuloplasty ring or prosthetic mitral valve, or previous transcatheter mitral valve surgery * Patients with active infective endocarditis * Patients with mitral stenosis * Any intracardiac mass, left ventricular or atrial thrombus detected by echocardiography * Severe coronary stenosis without surgical or interventional treatment or an acute myocardial infarction within 90 days * Combined with tricuspid, aortic valve or severe macrovascular pathology requiring surgical or interventional treatment * Severe pulmonary hypertension (pulmonary artery systolic pressure \> 70 mmHg measured by ultrasound or right heart catheter, if measured at the same time the right heart catheter measurement shall prevail). * Patients with severe right heart insufficiency * Hemodynamic instability, defined as systolic blood pressure \<90 mmHg in the absence of afterload-reducing drugs, cardiogenic shock, or use of intra-aortic balloon pump; * Had a stroke/transient ischemic attack (TIA) within 30 days or severe carotid stenosis (\> 70% stenosis on ultrasonography) * Have undergone transcatheter cardiovascular intervention (PCI) within 30 days, or cardiovascular surgery within 180 days * Have had a pacemaker or cardioverter-defibrillator (ICD) implanted, or have undergone cardiac resynchronization therapy (CRT, CRT-D) within 30 days * Patients with clear coagulation disorders and severe coagulation disorders, or with clear contraindications to the anticoagulant drugs * Known hypersensitivity to product composition * Patients with severe neurological pathology affecting cognitive ability * Patients with a life expectancy of \< 12 months * Have undergone a heart transplant or have recently been allocated a heart transplant donor * Being enrolled in an interventional clinical study of another device or drug * Patients diagnosed with hypertrophic cardiomyopathy, restrictive cardiomyopathy, infiltrative cardiomyopathy (e.g., amyloidosis, hemochromatosis), dilated cardiomyopathy, or constrictive pericarditis * Patients who are pregnant or planning to become pregnant within the next 12 months. Note: Female patients of childbearing age are required to undergo a pregnancy test within 14 days prior to the operation and the result should be negative, and additionally they should use a confirmed method of contraception * Other conditions that the investigator considers inappropriate for participation in this clinical study